RxDoctor Payments DataLook up a doctor →

Christopher Cooper, MD

Infectious Disease · Altamonte Springs, FLNPI 1154321057

Payments from drug & device makers

$278,060in general payments, 2019–2025

Across 611 payments — averaging $455.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paratek Pharmaceuticals, Inc.$95K
  • Takeda Pharmaceuticals U.S.A., Inc.$54K
  • Merck$49K
  • Shionogi Inc$38K
  • La Jolla Pharmaceutical Company$20K
  • Tetraphase Pharmaceuticals, Inc.$12K
  • plus $9K from 15 others

What the payments were for

  • Consulting fees$3,3451%
  • Speaking & faculty fees$230,32883%
  • Travel & lodging$28,59010%
  • Food & beverage$15,5586%
  • Education$2400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$278,060 in reported general payments places this provider in the 90th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$372,472
Medicare patients
377
Services billed
45,465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArikayceAmikacin Liposomal/Neb.Accessr11$167,748
Posaconazole12$23,424
Voriconazole19$4,337
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam27$4,011
CefuroximeCefuroxime Axetil26$2,937
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim19$1,100
Ethambutol Hcl12$1,099
Cephalexin27$877
Ciprofloxacin Hcl26$624
Doxycycline Hyclate20$355
Amoxicillin14$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Insmed, Inc.Arikayce$1,522$167,74811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Altamonte Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →